FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
- Written by PR Newswire Asia - News Pronto RSS
 |
- YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1
- First-in-class novel PTH replacement therapy
- Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval
SINGAPORE, Feb. 21, 2025 /PRNewswire/ --...
Read more: FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA